Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This study is a pivotal Phase 3, randomized, double-blind, 3-site, two-group trial assessing
the efficacy and safety of WR 279,396 Topical Cream and Paromomycin Alone Topical Cream in
subjects with CL in Panama. The primary objective of this study is to determine if WR 279,396
results in statistically superior final clinical cure rates of an index lesion when compared
with Paromomycin Alone for the treatment of CL in Panama expected to be caused by L
panamensis.
Phase:
Phase 3
Details
Lead Sponsor:
U.S. Army Medical Research and Development Command U.S. Army Medical Research and Materiel Command